Publication and availability
Tender notice/document availability: 02 June 2026 from 03:00 PM. The notice itself is dated 21 May 2026.
Loading
Loading…
Loading…
supply of medicine
Principal B.R.D. Medical College Gorakhpur · Gorakhpur, Uttar Pradesh2026_DGMET_1159717_1
Written by TenderKart AI from the documents published when it was generated. Check the tender for later corrigenda before you bid.
30 Jun 2026
30 Jul 2026
₹1 L
All important dates as they stand after corrigenda: publication, pre-bid/clarification deadline, bid submission deadline, bid opening, and bid validity period.
Tender notice/document availability: 02 June 2026 from 03:00 PM. The notice itself is dated 21 May 2026.
Clarifications could be sought from 03 June 2026 at 02:00 PM; the last clarification time is 29 June 2026 at 03:00 PM, through the portal Bid Management Window.
Latest amended deadline: 30 July 2026. The corrigendum changes the date from 30 June 2026 but does not restate the time; because all other terms remain unchanged, the corrected tender-form time of 05:00 PM remains the documented time.
Latest amended opening date: 31 July 2026. The corrigendum changes the date from 02 July 2026 but does not restate the time; under its unchanged-terms statement, 03:00 PM remains the documented time. Financial-bid opening will be communicated later only to technically qualified bidders.
The bid must remain valid for FY 2026-27 or until finalisation of the next tender in the next financial year; a shorter validity is non-responsive. The purchaser may request a written extension, which the bidder may refuse without EMD forfeiture.
Tender value or estimated cost, EMD/bid security (amount, acceptable forms, validity), tender document fees, performance security, and key payment terms.
No estimated tender value is stated. The supplied item-wise BOQ carries quantity 1 and estimated rate 0 for each line, so it does not establish an estimated procurement value.
INR 1,00,000, only as an FDR/TDR of minimum two-year validity from a nationalised bank, in favour of Principal, Medical College, Gorakhpur, payable at Gorakhpur, and issued from the company account. Upload the scan and submit the original. No interest is payable.
INR 1,180 including GST, non-refundable, by demand draft from a nationalised bank in favour of Principal, Medical College, Gorakhpur, payable at Gorakhpur. Upload the scan and deliver the original.
The corrected tender is internally inconsistent: the technical bid form requires 5% of total supply value, while the financial bid form states INR 1,00,000. The agreement clause also says the EMD is adjusted towards security money. No security validity is stated; obtain written clarification before pricing or award.
Rates are fixed for the contract period; quote in INR. Item evaluation is on L1 excluding GST/applicable Uttar Pradesh tax, while delivered cost includes incidental services, insurance and destination delivery. Payment is stated within 30 days after receipt of bill and supplies, but is expressly subject to fund availability and processing; no interest or legal action for delay is allowed, and supply cannot be stopped.
Every pass/fail eligibility and qualification requirement: experience and past performance, turnover/net worth, registrations and certifications, consortium/JV rules, and debarment or blacklisting conditions.
Bidder must be an original manufacturer/licensed pharmaceutical company in the healthcare sector. The corrected condition requires direct supply and states bills will be entertained only from the manufacturing company; the earlier distributor route was removed.
The bidder must swear that it has manufactured/marketed the quoted products for more than three consecutive financial years. It must also provide a performance statement listing hospital/unit orders, quantities, values, contractual and actual completion dates, and delay reasons. No minimum order value or number of past contracts is specified.
Average annual turnover must be above INR 50 crore during the last three consecutive financial years. Submit CA-certified turnover details and balance sheets for all three years.
Submit Drug Manufacturing/Marketing Licence compliant with revised Schedule M plus the approved drug list issued by the State Drug Control/Licensing Authority. A bidder may quote only drugs for which it has manufacturing units compliant with revised Schedule M.
Submit the State Drug Control/Licensing Authority performance-of-marketing/manufacturing certificate and applicable GMP/WHO/IPF/US-FDA/CEE/ISO/DGQA or equivalent certificate valid on the tender-opening date.
Submit latest Commercial Tax and Income Tax assessment orders and filed returns, Income Tax registration, GST registration/GST number, firm PAN, and firm-registration/status evidence with directors/partners/proprietor names.
A notarised affidavit must state that the firm has never been blacklisted, penalised or defaulted by any government institution/hospital during the last five years; has no pending judicial case and no conviction; the bidder has never been convicted or charged with crime in an Indian court; taxes for the last three years are up to date; and quoted rates are no higher than those offered to another government/autonomous government body.
Only firms registered for e-tendering on the Uttar Pradesh e-Procurement portal through UPLC are eligible to participate.
What is being procured: the work, supplies or services, deliverables and quantities, locations, phases, completion or delivery timelines, applicable standards, and notable exclusions.
Rate contract for supply of medicines/drugs for FY 2026-27 up to finalisation of the next financial-year tender, for B.R.D. Medical College and associated Nehru Hospital, Gorakhpur.
The corrected Schedule-1 and BOQ contain 1,360 medicine lines, from item 1 through item 1360. BOQ quantity is a placeholder 1 Nos per line and estimated rates are zero; actual procurement is demand-based and quantities may be increased or decreased at award without changing unit rates.
Supply F.O.R. hospital store/destination within three weeks of each individual supply order. Part supply is accepted only for hospital convenience, and payment follows completion of 100% supply.
Products must meet specification and Drugs and Cosmetics Act labelling; each unit must be marked “Hospital Supply, Not for sale” in red and must not carry MRP. Each batch requires analytical test report/data material and safety sheets. At receipt, drugs must have at least 75% shelf life remaining.
Rates remain effective for FY 2026-27 or until the next tender is finalised; the period may be extended by up to another year or until the next tender is finalised, whichever is later.
The complete checklist of documents to submit — mandatory vs conditional, with any prescribed formats, proformas or annexures — plus how to submit: portal and mode, envelope/cover structure, digital signature requirements, signing and attestation rules, and physical originals with their deadline.
Submit electronically at http://etender.up.nic.in in separate technical and financial schedules/packets. Technical labels are fee details, qualification details, e-bid form and technical specifications; financial labels are financial e-bid form and BOQ. Do not place financial documents in the technical bid.
Upload supporting documents as PDF and the downloaded BOQ as XLS. Use a Class-2/Class-3 DSC issued by a CCA-approved certifying authority. Every uploaded page/document must be digitally signed by the bidder or duly authorised signatory.
All submitted papers must be numbered and signed, arranged strictly in checklist order, and page numbers entered against checklist rows. Bid correspondence may be English or Hindi; Hindi documents require embedded/separate Hindi font files, and only English numerals may be used.
Hard copy of the complete technical bid is marked optional, by hand or registered post. However, original tender-fee DD and original EMD FDR/TDR are mandatory at the Principal’s office before technical-bid opening. The corrected form still states 30 June 2026 at 04:00 PM; the date corrigendum does not expressly extend this physical-original deadline.
Every corrigendum/addendum in order — what changed (original vs amended value), its impact, and the action for the bidder — ending with the values that finally apply.
The replacement corrected form updates the old 2023-24 tender form to 2026-27 and materially revises eligibility, performance and scope. It removes the earlier exceptional distributor appointment route and INR 2 crore distributor-turnover test, requiring direct supply/billing from the manufacturer; shortens delivery from four weeks to three; reduces minimum shelf life from 80% to 75%; changes agreement stamp paper from INR 500 to INR 100; updates turnover years to 2023-24, 2024-25 and 2025-26; changes EMD detail in the capability form from DD to FDR; and expands Schedule-1 from 1,094 to 1,360 items. Bidder action: use only MEDITENDERFORM.pdf and its 1,360-item schedule, not the superseded original form.
Bid submission was extended from 30 June 2026 to 30 July 2026, and technical opening from 02 July 2026 to 31 July 2026. It does not print revised times and says every other term remains unchanged. Bidder action: submit online by the extended date while seeking confirmation of exact times and the physical-original deadline.
Use the corrected 2026-27 form and 1,360-item schedule; online submission date 30 July 2026 and technical opening date 31 July 2026; EMD INR 1,00,000; fee INR 1,180; turnover above INR 50 crore; direct manufacturer supply/billing; delivery within three weeks; minimum 75% remaining shelf life. The performance-security amount and revised clock times/physical-original deadline remain unresolved internal issues.
Genuine conflicts within and across the documents (original vs corrigenda, clause vs annexure, tender document vs BOQ): both sides with citations, and which value prevails.
The corrected technical bid form says 5% of total supply value, but the corrected financial bid form says INR 1,00,000; the agreement clause additionally says EMD is adjusted towards security. No clause establishes which amount prevails, so this remains unresolved and needs written clarification.
The date corrigendum extends online submission/opening to 30/31 July, but the corrected form still requires original fee DD and EMD by 30 June at 04:00 PM. Since the corrigendum says all other terms are unchanged, no later physical deadline is documented. Neither value cleanly prevails for physical delivery; seek confirmation.
The date corrigendum labels its rows “Date & Time” but supplies dates only. The corrected form states 05:00 PM submission and 03:00 PM opening. On the document hierarchy, the date amendment prevails for dates and its unchanged-terms sentence leaves the original times in place, but bidders should obtain portal confirmation.
Checklist item 7 cites ITB 21.1 for turnover, but turnover is ITB 21.6; checklist item 8 cites ITB 21.6 for the affidavit, but the affidavit is ITB 21.9. The substantive clauses 21.6 and 21.9 prevail; submit both documents despite the cross-reference errors.
The invitation and ITB 21.1 allow an original manufacturer/licensed pharmaceutical company, while corrected ITB 21.8 says bills are entertained only from the manufacturing company. The more specific corrected ITB 21.8 controls supply/billing, but eligibility of a marketing-licence-only bidder is unclear.
The tender notice prints [email protected], while the corrected tender form prints [email protected]. The later corrected tender form prevails; bidders should use [email protected] and confirm delivery.
Only critical, tender-specific pre-bid queries that could materially change bid/no-bid, pricing, eligibility or contractual risk. Skip generic or obvious questions the documents already answer clearly.
Please confirm whether performance security is 5% of total supply value, INR 1,00,000, or only conversion/adjustment of EMD, and specify instrument, validity, submission deadline and release conditions.
Please publish the exact submission/opening times after the date extension and a revised deadline for physical originals. The corrigendum gives only 30/31 July dates, while the form still requires originals by 30 June at 04:00 PM.
Can a licensed pharmaceutical marketing company without its own manufacturing unit bid, or must every bidder be the manufacturing company for each quoted item? Also clarify whether third-party/loan-licence manufacturing is acceptable.
Please issue estimated annual quantities/consumption or a guaranteed minimum for each of 1,360 items. The BOQ shows quantity 1 and zero estimated rate, while procurement is demand-based and quantities may vary; this prevents capacity and logistics pricing.
Commercial, legal and execution risks a bidder should weigh: liquidated damages and penalties, unusual or one-sided clauses, tight timelines, and payment or security risks.
Although payment is stated within 30 days, it is conditional on fund availability and bill processing. The supplier waives interest/legal action for delayed payment and cannot stop supplies; part supplies are unpaid until 100% completion.
Failure to deliver within three weeks permits purchase from L2/L3 or the market, recovery of excess cost from bills/security, security forfeiture and blacklisting/debarment. Non-execution of the agreement within 15 days can also trigger blacklisting and forfeiture.
Random testing charges up to 1% are borne by the supplier. A sample/supply discrepancy can require repayment of the whole bill with 2% compound interest compounded monthly plus full legal/financial responsibility for patient harm; substandard drugs can also lead to non-payment of consumed stock and blacklisting.
Hospital may return supplies for inventory management, require replacement of near-expiry/slow-moving stock at supplier cost, substitute approved items of equal value, and recover expiry losses from security or bills. Required remaining shelf life is 75%.
Rates cannot be increased during the contract, but price/tax reductions must be passed through immediately. Failure may attract severe financial penalty, cancellation or blacklisting. Contract duration may extend up to another year or until the next tender is finalised, whichever is later.
Purchaser may reject any/all bids without liability, approve an item based on clinician quality preference rather than price, and treats the Principal’s decision on disputes as final and binding, subject to Gorakhpur civil-court jurisdiction.
The unresolved performance-security amount and unamended physical-original deadline create pass/fail and cash-collateral risk. Obtain written clarification before committing security instruments.
The inviting authority and relevant contacts: office, person, designation, address, phone and email — and which address receives physical submissions, if any.
Principal, B.R.D. Medical College, Gorakhpur, Uttar Pradesh 273013. Communication and mandatory physical originals are addressed to the Principal’s office at B.R.D. Medical College, Gorakhpur.
Telephone: (0551) 2501736. Fax: (0551) 2501736. Email: [email protected]. Website: www.brdmc.ac.in. No named individual contact is identified beyond the Principal/office.
Committee Room, Principal Office, B.R.D. Medical College, Gorakhpur 273013, Uttar Pradesh.